{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Expansion+Cohort&page=2", "query": { "intervention": "Expansion Cohort", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Expansion+Cohort&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T03:37:24.034Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05970497", "title": "A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Melanoma Stage III", "Melanoma Stage IV", "Cutaneous Melanoma" ], "interventions": [ { "name": "KB707", "type": "BIOLOGICAL" }, { "name": "Opdualag", "type": "DRUG" }, { "name": "KEYTRUDA ®( Pembrolizumab)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Krystal Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2023-10-31", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-09-26T03:37:24.034Z", "location_count": 15, "location_summary": "Los Angeles, California • Rancho Santa Margarita, California • Weston, Florida + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Rancho Santa Margarita", "state": "California" }, { "city": "Weston", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05970497" }, { "nct_id": "NCT01005797", "title": "Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cancer", "Non Small Cell Lung Cancer (NSCLC)", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Panobinostat (LBH589), Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2009-11", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-03-03", "last_synced_at": "2026-09-26T03:37:24.034Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01005797" }, { "nct_id": "NCT04890613", "title": "Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "CX-5461", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Senhwa Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2021-09-08", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-09-26T03:37:24.034Z", "location_count": 6, "location_summary": "Santa Monica, California • Tampa, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04890613" }, { "nct_id": "NCT04910568", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cevostamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2021-07-26", "completion_date": "2028-12-21", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-26T03:37:24.034Z", "location_count": 6, "location_summary": "Duarte, California • Irvine, California • Denver, Colorado + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04910568" }, { "nct_id": "NCT01397708", "title": "Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "INXN-2001", "type": "BIOLOGICAL" }, { "name": "INXN-1001", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2011-08", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-09-26T03:37:24.034Z", "location_count": 9, "location_summary": "Los Angeles, California • Park Ridge, Illinois • Goshen, Indiana + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01397708" }, { "nct_id": "NCT05087992", "title": "A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Cancer, Metastatic" ], "interventions": [ { "name": "BI 905711", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-11-24", "completion_date": "2023-11-14", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-09-26T03:37:24.034Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05087992" }, { "nct_id": "NCT07818018", "title": "A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Cancer", "Advanced Esophageal Cancer", "Gastric Cancer", "Advanced Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "Intratumoral 2141-V11", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Fluoropyrimidine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-09-04", "completion_date": "2029-09-04", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-26T03:37:24.034Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07818018" }, { "nct_id": "NCT05989724", "title": "A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Breast Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "SON-DP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Qurgen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2023-09-19", "completion_date": "2026-03", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-09-26T03:37:24.034Z", "location_count": 5, "location_summary": "Gilbert, Arizona • Detroit, Michigan • Huntersville, North Carolina + 2 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05989724" }, { "nct_id": "NCT05614739", "title": "FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Neoplasms", "Neoplasm Metastasis", "Ureteral Neoplasms" ], "interventions": [ { "name": "Vepugratinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "enfortumab vedotin", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 677, "start_date": "2023-01-12", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-26T03:37:24.034Z", "location_count": 41, "location_summary": "Tucson, Arizona • Duarte, California • Los Angeles, California + 29 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05614739" }, { "nct_id": "NCT06237881", "title": "A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Melanoma", "Lung Neoplasms", "Head and Neck Neoplasms" ], "interventions": [ { "name": "KSQ-001EX", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2024-01-31", "completion_date": "2029-01-01", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-26T03:37:24.034Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06237881" } ] }